Calcium glubionate

Identification

Name
Calcium glubionate
Accession Number
DB13142
Type
Small Molecule
Groups
Approved
Description

Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets.

Structure
Thumb
Synonyms
  • (D-gluconato)(lactobionato)calcium
  • Calcium D-gluconate lactobionate
  • Calcium glubionate anhydrous
  • Glubionate calcium
Product Ingredients
IngredientUNIICASInChI Key
Calcium D-gluconate lactobionate monohydrate3CF7K0SD0Q12569-38-9OKRXSXDSNLJCRS-LMMYEKIPSA-L
Categories
UNII
93H20IU3DN
CAS number
97635-31-9
Weight
Average: 592.513
Monoisotopic: 592.1163697
Chemical Formula
C18H32CaO19
InChI Key
YPCRNBPOUVJVMU-DTRXJECDSA-L
InChI
InChI=1S/C12H22O12.C6H12O7.Ca/c13-1-3(15)10(7(18)8(19)11(21)22)24-12-9(20)6(17)5(16)4(2-14)23-12;7-1-2(8)3(9)4(10)5(11)6(12)13;/h3-10,12-20H,1-2H2,(H,21,22);2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t3-,4-,5+,6-,7-,8-,9-,10-,12+;2-,3-,4+,5-;/m11./s1
IUPAC Name
{[(2R,3R,4R,5R)-2,3,5,6-tetrahydroxy-4-{[(2S,3R,4R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexanoyl]oxy}calcio (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate
SMILES
OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O[Ca]OC(=O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@@H](O)[C@H]1O)[C@H](O)CO

Pharmacology

Indication

Calcium glubionate is indicated to treat conditions caused by low calcium levels such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany). It may also be used in certain patients to make sure they are getting enough calcium (e.g., women who are pregnant, nursing, or postmenopausal, people taking certain medications such as phenytoin, phenobarbital, or prednisone).

Pharmacodynamics
Not Available
Mechanism of action

Essential for nervous, muscular, and skeletal systems. Maintain cell membrane and capillary permeability. Act as an activator in the transmission of nerve impulses and contraction of cardiac, skeletal, and smooth muscle. Essential for bone formation and blood coagulation.

Absorption

Minimal unless chronic, high doses; absorption predominantly in the duodenum and dependent on calcitriol and vitamin D; mean absorption of calcium intake varies with age (infants 60%, prepubertal children 28%, pubertal children 34%, adults 25%); during pregnancy, calcium absorption doubles; calcium is absorbed in soluble, ionized form; solubility of calcium is increased in an acid environment (IOM 2011); decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia

Volume of distribution

Primarily in bones, teeth

Protein binding

~40%, primarily to albumin

Metabolism
Not Available
Route of elimination

Primarily feces (75%; as unabsorbed calcium); urine (22%)

Half life
Not Available
Clearance
Not Available
Toxicity

Assess patient for nausea, vomiting, anorexia, thirst, severe constipation, paralytic ileus, and bradycardia

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1alpha-Hydroxyvitamin D5The risk or severity of adverse effects can be increased when Calcium glubionate is combined with 1alpha-Hydroxyvitamin D5.
3-Aza-2,3-Dihydrogeranyl DiphosphateCalcium glubionate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
3,5-diiodothyropropionic acidThe therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Calcium glubionate.
AbaloparatideThe therapeutic efficacy of Abaloparatide can be decreased when used in combination with Calcium glubionate.
AcetyldigitoxinCalcium glubionate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin.
AcetyldigoxinCalcium glubionate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigoxin.
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Calcium glubionate.
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium glubionate.
AlfacalcidolThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Alfacalcidol.
AmiodaroneThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium glubionate.
Food Interactions
Not Available

References

General References
  1. Drug Information [Link]
External Links
PubChem Compound
131704325
PubChem Substance
347829259
Wikipedia
Calcium_glubionate
ATC Codes
A12AA02 — Calcium glubionate

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility47.2 mg/mLALOGPS
logP-2.5ALOGPS
logP-9.6ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)11.32ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count17ChemAxon
Hydrogen Donor Count13ChemAxon
Polar Surface Area334.05 Å2ChemAxon
Rotatable Bond Count17ChemAxon
Refractivity107.1 m3·mol-1ChemAxon
Polarizability50.76 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on November 04, 2016 14:50 / Updated on November 02, 2018 09:00